On this page

Naproxen

Naproxen Sodium · Tablet, Film Coated

Over-the-counter ANDA Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Naproxen
Generic name
Naproxen Sodium
Dosage form
Tablet, Film Coated
Route
Oral
Marketing category
ANDA · ANDA
Labeler
Amerisource Bergen
Product type
Human Otc Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
6
Packages
10
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Naproxen Sodium 220 mg/1 849431 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Tablet, Film Coated
Route of administration
Oral
Presentations
16

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Anti-Inflammatory Agents EPC All 251 members
Cyclooxygenase Inhibitors [MoA] MoA All 251 members
Non-Steroidal [CS] CS All 251 members
Nonsteroidal Anti-inflammatory Drug [EPC] EPC All 251 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
204872
Application type
ANDA · Abbreviated New Drug Application
Approval date
January 23, 2017
Sponsor
LNK INTL INC
Products on application
1
Submissions recorded
6
Products approved under application 204872.
Product Trade name Form Strength Ingredient Status TE Flags
204872-001 NAPROXEN SODIUM TABLET NAPROXEN SODIUM Over-the-counter —

Approval history

Source: Drugs@FDA
Most recent submissions on application 204872.
Type No. Action Status Date Review
Supplement 8 Labeling Approved September 16, 2025 Standard
Supplement 6 Labeling Approved September 16, 2025 Standard
Supplement 2 Labeling Approved September 16, 2025 Standard
Supplement 1 Labeling Approved September 16, 2025 Standard
Supplement 10 Manufacturing (CMC) Approved April 23, 2025 Unknown
Original application 1 Approved January 23, 2017 —

Review documents

  • 0 · Original application · January 27, 2017

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251028). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN OTC DRUG · 20251028

Indications and Usage

openFDA Drug Labeling

Uses temporarily relieves minor aches and pains due to: headache muscular aches the common cold toothache backache menstrual cramps minor pain of arthritis temporarily reduces fever

Purpose Pain reliever/fever reducer

Dosage and Administration

openFDA Drug Labeling

Directions do not take more than directed the smallest effective dose should be used drink a full glass of water with each dose adults and children 12 years and older take 1 tablet every 8 to 12 hours while symptoms last for the first dose you may take 2 tablets within the first hour do not exceed 2 tablets in any 8- to 12-hour period do not exceed 3 tablets in a 24-hour period children under 12 years: ask a doctor

Warnings Allergy alert: Naproxen sodium may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include: asthma (wheezing) skin reddening shock blisters rash facial swelling hives If an allergic reaction occurs, stop use and seek medical help right away. Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you have had stomach ulcers or bleeding problems take a blood thinning (anticoagulant) or steroid drug take other drugs containing prescription or nonprescription NSAIDs [aspirin, ibuprofen, naproxen, or others] are age 60 or older have 3 or more alcoholic drinks every day while using this product take more or for a longer time than directed Heart attack and stroke warning: NSAIDs, except aspirin, increase the risk of heart attack, heart failure, and stroke. These can be fatal. The risk is higher if you use more than directed or for longer than directed. Do not use if you have ever had an allergic reaction to any other pain reliever/fever reducer right before or after heart surgery Ask a doctor before use if the stomach bleeding warning applies to you you have a history of stomach problems, such as heartburn you are taking a diuretic you have high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, or had a stroke you have problems or serious side effects from taking pain relievers or fever reducers Ask a doctor or pharmacist before use if you are under a doctor’s care for any serious condition taking aspirin for heart attack or stroke, because naproxen may decrease this benefit of aspirin taking any other drug When using this product take with food or milk if stomach upset occurs Stop use and ask a doctor if you experience any of the following signs of stomach bleeding: feel faint vomit blood have bloody or black stools have stomach pain that does not get better you have symptoms of heart problems or stroke: leg swelling chest pain slurred speech trouble breathing weakness in one part or side of body pain gets worse or lasts more than 10 days fever gets worse or lasts more than 3 days you have difficulty swallowing it feels like the pill is stuck in your throat redness or swelling is present in the painful area any new symptoms appear If pregnant or breast-feeding, ask a health professional before use. It is especially important not to use naproxen sodium at 20 weeks or later in pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

Do not use if you have ever had an allergic reaction to any other pain reliever/fever reducer right before or after heart surgery

Ask a Doctor

openFDA Drug Labeling

Ask a doctor before use if the stomach bleeding warning applies to you you have a history of stomach problems, such as heartburn you are taking a diuretic you have high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, or had a stroke you have problems or serious side effects from taking pain relievers or fever reducers

Stop use and ask a doctor if you experience any of the following signs of stomach bleeding: feel faint vomit blood have bloody or black stools have stomach pain that does not get better you have symptoms of heart problems or stroke: leg swelling chest pain slurred speech trouble breathing weakness in one part or side of body pain gets worse or lasts more than 10 days fever gets worse or lasts more than 3 days you have difficulty swallowing it feels like the pill is stuck in your throat redness or swelling is present in the painful area any new symptoms appear

Active Ingredient

openFDA Drug Labeling

Active ingredient (in each tablet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug

Adverse event reports

Source: openFDA FAERS
165,056
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: NAPROXEN SODIUM. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
46122-562-58 46122-562 Amerisource Bergen 1 BOTTLE, PLASTIC in 1 CARTON (46122-562-58) / 24 TABLET, FILM COATED in 1 BOTTLE, PLASTIC February 1, 2019
46122-562-71 46122-562 Amerisource Bergen 1 BOTTLE, PLASTIC in 1 CARTON (46122-562-71) / 50 TABLET, FILM COATED in 1 BOTTLE, PLASTIC February 1, 2019
46122-562-78 46122-562 Amerisource Bergen 1 BOTTLE, PLASTIC in 1 CARTON (46122-562-78) / 100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC February 1, 2019
46122-564-71 46122-564 Amerisource Bergen 1 BOTTLE, PLASTIC in 1 CARTON (46122-564-71) / 50 TABLET, FILM COATED in 1 BOTTLE, PLASTIC February 1, 2019
46122-564-78 46122-564 Amerisource Bergen 1 BOTTLE, PLASTIC in 1 CARTON (46122-564-78) / 100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC February 1, 2019
46122-564-81 46122-564 Amerisource Bergen 200 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (46122-564-81) February 1, 2019
21130-674-52 21130-674 Better Living Brands, LLC 1 BOTTLE, PLASTIC in 1 CARTON (21130-674-52) / 90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC October 4, 2023
55319-406-15 55319-406 Family Dollar Services Inc 1 BOTTLE, PLASTIC in 1 CARTON (55319-406-15) / 50 TABLET, FILM COATED in 1 BOTTLE, PLASTIC December 15, 2023
55319-717-08 55319-717 Family Dollar Services Inc 1 BOTTLE, PLASTIC in 1 CARTON (55319-717-08) / 24 TABLET, FILM COATED in 1 BOTTLE, PLASTIC December 13, 2023
50844-261-08 50844-261 L.N.K. International, Inc. 1 BOTTLE, PLASTIC in 1 CARTON (50844-261-08) / 24 TABLET, FILM COATED in 1 BOTTLE, PLASTIC August 6, 2019
46122-562 46122-562 Amerisource Bergen — February 1, 2019
46122-564 46122-564 Amerisource Bergen — February 1, 2019
21130-674 21130-674 Better Living Brands, LLC — October 4, 2023
55319-406 55319-406 Family Dollar Services Inc — December 15, 2023
55319-717 55319-717 Family Dollar Services Inc — December 13, 2023
50844-261 50844-261 L.N.K. International, Inc. — August 6, 2019

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.